ECM
NVO

EagleClaw Capital Management’s Novo Nordisk NVO Stock Holding History

EagleClaw Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Sell
63,650
-550
-0.9% -$23.6K 0.41% 63
2026
Q1 		$2.36M Sell
64,200
-450
-0.7% -$21.3K 0.33% 70
2025
Q4 		$3.29M Buy
64,650
+500
+0.8% +$25.6K 0.48% 56
2025
Q3 		$3.56M Sell
64,150
-1,000
-2% -$58.5K 0.5% 53
2025
Q2 		$4.5M Hold
65,150
– – 0.67% 42
2025
Q1 		$4.52M Sell
65,150
-700
-1% -$57.8K 0.71% 45
2024
Q4 		$5.66M Hold
65,850
– – 0.9% 36
2024
Q3 		$7.84M Buy
65,850
+2,575
+4% +$343K 1.31% 26
2024
Q2 		$9.03M Sell
63,275
-500
-0.8% -$66.3K 1.63% 19
2024
Q1 		$8.19M Sell
63,775
-1,225
-2% -$146K 1.48% 20
2023
Q4 		$6.72M Buy
65,000
+500
+0.8% +$49.4K 1.4% 25
2023
Q3 		$5.87M Buy
64,500
+300
+0.5% +$26.4K 1.33% 27
2023
Q2 		$5.19M Sell
64,200
-500
-0.8% -$40.8K 1.19% 32
2023
Q1 		$5.15M Sell
64,700
-3,750
-5% -$266K 1.21% 32
2022
Q4 		$4.63M Sell
68,450
-300
-0.4% -$17.6K 1.12% 30
2022
Q3 		$3.42M Hold
68,750
– – 0.96% 36
2022
Q2 		$3.83M Hold
68,750
– – 1.04% 31
2022
Q1 		$3.82M Sell
68,750
-1,900
-3% -$97.5K 0.88% 38
2021
Q4 		$3.96M Sell
70,650
-250
-0.4% -$13.5K 0.87% 36
2021
Q3 		$3.4M Sell
70,900
-4,600
-6% -$222K 0.88% 37
2021
Q2 		$3.16M Buy
75,500
+1,950
+3% +$75.6K 0.82% 37
2021
Q1 		$2.48M Buy
73,550
+2,650
+4% +$94.4K 0.71% 44
2020
Q4 		$2.47M Sell
70,900
-7,400
-9% -$256K 0.79% 40
2020
Q3 		$2.72M Buy
78,300
+1,600
+2% +$53.3K 0.95% 32
2020
Q2 		$2.51M Sell
76,700
-5,800
-7% -$185K 0.97% 31
2020
Q1 		$2.48M Sell
82,500
-398
-0.5% -$11.9K 1.17% 30
2019
Q4 		$2.4M Buy
82,898
+2,000
+2% +$55.4K 0.88% 41
2019
Q3 		$2.09M Sell
80,898
-250
-0.3% -$6.32K 0.85% 38
2019
Q2 		$2.07M Buy
81,148
+150
+0.2% +$3.71K 0.9% 34
2019
Q1 		$2.12M Buy
80,998
+450
+0.6% +$11.1K 0.97% 31
2018
Q4 		$1.86M Sell
80,548
-2,750
-3% -$61.1K 0.97% 31
2018
Q3 		$1.96M Buy
83,298
+48
+0.1% +$1.17K 0.86% 38
2018
Q2 		$1.92M Sell
83,250
-300
-0.4% -$7.13K 0.93% 32
2018
Q1 		$2.06M Sell
83,550
-200
-0.2% -$5.25K 1.04% 29
2017
Q4 		$2.25M Hold
83,750
– – 1.13% 32
2017
Q3 		$2.01M Buy
83,750
+800
+1% +$18.1K 1.14% 33
2017
Q2 		$1.78M Buy
82,950
+1,250
+2% +$25.2K 1.04% 32
2017
Q1 		$1.4M Buy
81,700
+600
+0.7% +$10.4K 0.84% 47
2016
Q4 		$1.45M Sell
81,100
-5,000
-6% -$90.6K 0.92% 41
2016
Q3 		$1.79M Buy
86,100
+1,300
+2% +$32.2K 1.14% 33
2016
Q2 		$2.28M Buy
84,800
+1,900
+2% +$52.1K 1.52% 24
2016
Q1 		$2.25M Sell
82,900
-1,050
-1% -$28.1K 1.52% 25
2015
Q4 		$2.44M Buy
83,950
+700
+0.8% +$19.4K 1.62% 20
2015
Q3 		$2.25M Sell
83,250
-1,450
-2% -$41.1K 1.59% 24
2015
Q2 		$2.32M Sell
84,700
-150
-0.2% -$4.22K 1.49% 26
2015
Q1 		$2.26M Buy
84,850
+1,400
+2% +$32.2K 1.47% 25
2014
Q4 		$1.77M Sell
83,450
-700
-0.8% -$15.6K 1.17% 35
2014
Q3 		$2.01M Buy
84,150
+600
+0.7% +$13.8K 1.36% 29
2014
Q2 		$1.93M Sell
83,550
-600
-0.7% -$13.2K 1.31% 31
2014
Q1 		$1.92M Buy
+84,150
New +$1.79M 1.39% 28

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EagleClaw Capital Management's NVO Position: Q2 2026 in Review

EagleClaw Capital Management reduced its Novo Nordisk (NVO) stake by 0.86% in Q2 2026, selling an estimated $23.6K and leaving 63,650 shares worth $3.05M. The position accounts for 0.41% of the portfolio, ranked #63.

EagleClaw Capital Management first reported a position in NVO in Q1 2014 and has held it in 50 quarters since. The position peaked at $9.03M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • EagleClaw Capital Management held 63,650 shares of Novo Nordisk worth $3.05M as of Q2 2026.
  • EagleClaw Capital Management sold 550 Novo Nordisk shares in Q2 2026, an estimated $23.6K.
  • Novo Nordisk made up 0.41% of EagleClaw Capital Management's portfolio in Q2 2026, its #63 holding.
  • EagleClaw Capital Management first reported a position in Novo Nordisk in Q1 2014 and has held it in 50 quarters since.
  • EagleClaw Capital Management's Novo Nordisk position peaked at $9.03M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.